EEF2K (eukaryotic elongation factor 2 kinase)

Show full item record

Files in this item

PDF 01-2016-EEF2KID40411ch16p12.pdf 186.7Kb

Pour citer ce document :
URI:  |   DOI :
Title: EEF2K (eukaryotic elongation factor 2 kinase)
Author: Ozpolat, Bulent; Ozkayar, Ozgur
Abstract: Eukaryotic elongation factor 2 kinase (eEF-2K) (also known as Calmodulin (CaM)-dependent elongation factor 2 kinase,CaMKIII) is an unusual calcium/calmodulin (Ca2+/CaM)-dependent Threonin kinase that controls the rate of the elongation phase of protein synthesis through phosphorylating elongation factor 2 (eEF2) (Nairn et al., 1985; Ryazanov 1987; Mitsui et al., 1993; Redpath et al., 1993). Phosphorylation of eEF2 on Thr-56 disrupts the interaction between eEF-2 and the ribosome, leading to reduced protein synthesis. eEF-2K is regulated by phosphorylation by multiple signaling pathways and kinases at 11 different phosphorylation sides (Ryazanov et al., 1988; Carlberg et al., 1990; Abramczyk et al., 2011; Browne et al., 2004; Marshall et al., 2012; Chafouleas et al., 1981; Bowden et al., 2013). Hypoxia, nutrient deprivation and metabolic stress are all known to stimulate eEF-2K through activation of AMPK (Chafouleas et al., 1981).The activity of eEF-2K is increased in rapidly proliferating malignant cells and in cancer specimens, but is absent in normal adjacent tissues (Ashour et al., 2014b). eEF-2K promotes cell proliferation, invasion and tumorigenesis of some cancers. eEF-2K expression (mRNA) correlates with poor patient survival and prognosis (outcome) in some solid tumors, including breast , pancreatic cancer and glioblastoma (Meric-Bernstam et al., 2012). The activity of this kinase is increased in many cancers and may be a potential therapeutic target in some cancer
Subject: elongation; protein translation; proliferation; invasion; prognosis; survival; cancer; Genes Section; Acetophenones/administration & dosage; Benzopyrans/administration & dosage; Cell Line, Tumor; Elongation Factor 2 Kinase/*genetics/metabolism; Epithelial-Mesenchymal Transition/genetics; GTP-Binding Proteins; Gene Expression Regulation, Neoplastic/drug effects; Humans; Integrin beta1/*biosynthesis/genetics; Neoplasm Invasiveness/genetics; Pancreatic Neoplasms/*genetics/pathology; RNA, Small Interfering; Receptors, Urokinase Plasminogen Activator/*biosynthesis/genetics; Signal Transduction/genetics; Transglutaminases/*biosynthesis; src-Family Kinases/biosynthesis/genetics; Animals; Blood Pressure/drug effects/physiology; Cells, Cultured; Disease Models, Animal; Elongation Factor 2 Kinase/antagonists & inhibitors/drug effects/*physiology
Publisher: ARMGHM - Atlas Génétique des Cancers
Date: 2016

This item appears in the following Collection(s)

Show full item record

Advanced Search